A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.
about
The detection, treatment, and biology of epithelial ovarian cancerBeyond CA125: the coming of age of ovarian cancer biomarkersOvarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for PreventionHarnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian CancerOvarian serous carcinoma: recent concepts on its origin and carcinogenesisEGFR/HER-targeted therapeutics in ovarian cancerRecent concepts of ovarian carcinogenesis: type I and type IISalpingectomy as a means to reduce ovarian cancer riskThe oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention"Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentMolecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tubeInduction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.The Functions of MicroRNA-200 Family in Ovarian Cancer: Beyond Epithelial-Mesenchymal Transition.Morphological and immunohistochemical study of ovarian and tubal dysplasia associated with tamoxifenOvulation and extra-ovarian origin of ovarian cancerA genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube.The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review.IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesisDecreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinomaRisk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutationsModeling high-grade serous ovarian carcinogenesis from the fallopian tubeHereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic markerProgesterone action in breast, uterine, and ovarian cancers.Carcinomas of Distal Fallopian Tube and Their Association with Tubal Intraepithelial Carcinoma: Do They Share a Common "Precursor" Lesion? Loss of Heterozygosity and Immunohistochemical Analysis Using PAX 2, WT-1, and P53 Markers.Comparison of candidate serologic markers for type I and type II ovarian cancerCharacterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinomaSignificance of p53 expression in background endometrium in endometrial carcinoma.Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells.Mutant p53 expression in fallopian tube epithelium drives cell migrationWild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival.Ovarian cancer survival by tumor dominance, a surrogate for site of origin.Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.
P2860
Q21198791-C5D70691-8A4A-4B9B-A6E9-880D43FCE3DDQ24651567-F5775A21-5CFB-4DB7-B746-467720AE0336Q26747279-6296CEAD-2CB7-4190-AD51-8D78327961D3Q26801525-4AB93456-5A00-4368-A2FD-9A6EC532CA4CQ26822545-51A1ECBB-4D30-4622-A2CB-FCE1C0204F18Q26863231-676155F0-D574-4D44-A6E2-3A5EA77C2D3DQ27009487-F0785E6B-5D4A-4E27-AFBE-DE2026771F20Q27011949-064E7035-E97A-4C72-8FD8-75DACE0A17C6Q27025315-78C694CE-F659-4444-9412-298501637EFAQ28066904-13EFBF0D-0A39-41EB-A54E-ED896C87A476Q30430198-C3B98616-DEF4-427F-980D-9B1FE95B24C9Q33510967-F7E7BAE4-A5D5-4FE5-ADA7-89FDDEACCCB5Q33521710-34B05354-563F-480D-A896-7AFD2181EF62Q33633387-00B3B5E6-B017-44B4-BCA7-3DFFA19546CAQ33815261-ED094675-6D20-433C-8DF5-2D491FD552ACQ33838714-15E53EEB-CBDE-472C-BA96-EAC33733747EQ33851264-FD84833F-8B01-4E72-973E-89FDB4CEDE5BQ34063581-063F46F8-ED19-480B-8D4B-3CEFA33BEB40Q34111959-B033EDC2-294C-46A3-A996-50D5C19264C5Q34125241-3803104B-23BF-4F20-9AAB-273A9BFDB7CCQ34201837-660B09A0-FF0B-4BFE-8389-9E14343EB5C8Q34288214-9B656F38-3536-4836-BF54-753E965E2BF7Q34391423-ED2E3D67-82F1-43B1-9CFB-DB811938FBACQ34407218-AB688BB5-C24A-45BC-B148-192EA56C89C2Q34468574-575CBB77-7D21-4A57-B579-A33EB8153E0FQ34595670-FABF2279-5A00-4687-B3A8-8793B22E2BCDQ34811314-1DF7783C-ED9C-4828-B20A-25F5A13E7FF4Q34938333-1AFE6FD5-CA99-457E-B85A-988D094345C0Q34977063-CE267E9C-4F87-478F-810A-50190A811D37Q35089974-F002A2E4-CBE9-4194-AA2D-C0A53D0339ABQ35108906-794A50AF-8325-4CFF-9B79-771A58309241Q35145201-2B2B04E8-DED0-4FB9-AA5F-E2870E3294CAQ35154077-41652FED-FF8C-4C67-A221-1E085B953A00Q35519808-6716F2D3-2F4A-4013-B2FA-E87330FBB304Q35580913-33347DA2-0F85-49E6-9BC4-317460736341Q35822970-81804DC0-87F6-42A2-9E96-C500A7F25BC2Q35855276-9C505F74-57A7-470C-882A-5DD952E2352EQ35872729-9521F87C-D79A-4BB1-967C-E58CF90F732EQ36032691-07091FE0-AF5A-4C69-AE52-A50D6A356695Q36173170-25DA514E-954B-4FB8-ABA3-4116851D7D8F
P2860
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
A candidate precursor to pelvi ...... rom women with BRCA mutations.
@ast
A candidate precursor to pelvi ...... rom women with BRCA mutations.
@en
A candidate precursor to pelvic serous cancer
@nl
type
label
A candidate precursor to pelvi ...... rom women with BRCA mutations.
@ast
A candidate precursor to pelvi ...... rom women with BRCA mutations.
@en
A candidate precursor to pelvic serous cancer
@nl
prefLabel
A candidate precursor to pelvi ...... rom women with BRCA mutations.
@ast
A candidate precursor to pelvi ...... rom women with BRCA mutations.
@en
A candidate precursor to pelvic serous cancer
@nl
P2093
P2860
P1433
P1476
A candidate precursor to pelvi ...... rom women with BRCA mutations.
@en
P2093
Aasia Saleemuddin
Ann K Folkins
Christopher P Crum
Elke A Jarboe
Judy E Garber
Michael G Muto
Michael J Callahan
Ronny Drapkin
Yonghee Lee
P2860
P304
P356
10.1016/J.YGYNO.2008.01.012
P407
P577
2008-03-14T00:00:00Z